Symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals.
Smith-Jeffcoat SE, Biddle JE, Talbot HK, Morrisey KG, Stockwell MS, Maldonado Y, McLean HQ, Ellingson KD, Bowman NM, Asturias E, Mellis AM, Johnson S, Kirking HL, Rolfes MAR, Olivo V, Merrill L, Battan-Wraith S, Sano E, McLaren SH, Vargas CY, Goodman S, Sarnquist CC, Govindaranjan P, Petrie JG, Belongia EA, Ledezma K, Pryor K, Lutrick K, Bullock A, Yang A, Haehnel Q, Rao S, Zhu Y, Schmitz J, Hart K, Grijalva CG, Salvatore PP.
Smith-Jeffcoat SE, et al. Among authors: ellingson kd.
Clin Infect Dis. 2023 Nov 14:ciad696. doi: 10.1093/cid/ciad696. Online ahead of print.
Clin Infect Dis. 2023.
PMID: 37963102